A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

被引:3
|
作者
Pemmaraju, Naveen
Marconi, Giovanni
Todisco, Elisabetta
Montesinos, Pau
Lane, Andrew A.
Sweet, Kendra
Wang, Eunice S.
Deconinck, Eric
Rizzieri, David A.
Walter, Roland B.
Aribi, Ahmed
Lebon, Delphine
Levy, Moshe Y.
Mazzarella, Luca
Martinelli, Giovanni
Gigli, Federica
Erba, Harry P.
Acuna-Cruz, Evelyn
Konopleva, Marina
Kantarjian, Hagop
Sloss, Callum M.
Wang, Jiuzhou
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
DeAngelo, Daniel J.
Daver, Naval
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Ist Seragnoli, Bologna, Italy
[3] European Inst Oncol IRCCS, Div Onco Hematol, Milan, Italy
[4] Hosp Univ & Politecn La Fe, Valencia, Spain
[5] Dana Farber Boston Childrens Canc & Blood Disorde, Dept Med Oncol, Boston, MA USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[7] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[8] Besancon Univ Hosp, Clin Hematol, Besancon, France
[9] Duke Univ Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Med, Durham, NC USA
[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[11] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA USA
[12] CHU Amiens, Hematol Dept, Amiens, France
[13] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[14] European Inst Oncol, Milan, Italy
[15] Inst Hematol LeA Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[16] European Inst Oncol, Milan, Italy
[17] Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[19] ImmunoGen, Waltham, MA USA
[20] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
关键词
D O I
10.1182/blood-2021-146681
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
4429
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class
    Stelte-Ludwig, Beatrix
    Schomber, Tibor
    Izumi, Raquel
    Wong, Harvey
    Frigault, Melanie M.
    Rebstock, Anne-Sophie
    Ludwig, Sebastian
    Mithal, Arushi
    Johnson, Amy J.
    Hamdy, Ahmed
    BLOOD, 2023, 142
  • [32] CD123CAR displays clinical activity in relapsed/refractory (r/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study.
    Budde, Lihua E.
    Song, Joo
    Del Real, Marissa
    Kim, Young
    Toribio, Candida
    Wood, Brent
    Wagner, Jamie
    Marcucci, Emanuela
    Stein, Anthony
    Marcucci, Guido
    Brown, Christine E.
    Forman, Stephen J.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 33 - 34
  • [33] INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
    Cortes, J.
    DeAngelo, D.
    Wang, E.
    Arana-Yi, C.
    Zweidler-McKay, P.
    Munteanu, M.
    Andreu-Vieyra, C.
    Erba, H.
    Blum, W.
    Traer, E.
    HAEMATOLOGICA, 2017, 102 : 217 - 218
  • [34] Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Cortes, Jorge E.
    DeAngelo, Daniel J.
    Erba, Harry P.
    Traer, Elie
    Papadantonakis, Nikolaos
    Arana-Yi, Cecilia
    Blum, William
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Zweidler-McKay, Patrick A.
    Wang, Eunice S.
    BLOOD, 2018, 132
  • [35] CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123
    Hu, Xiaoyi
    Ediriwickrema, Asiri
    Saleem, Atif
    Tan, Brent
    Pemmaraju, Naveen
    Mannis, Gabriel N.
    LEUKEMIA RESEARCH, 2024, 139
  • [36] A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
    Stathis, Anastasios
    Freedman, Arnold S.
    Flinn, Ian W.
    Maddocks, Kami J.
    Weitman, Steven
    Berdeja, Jesus G.
    Mejia, Alex V.
    Zucca, Emanuele
    Green, Rebecca
    Romanelli, Angela
    Zildjian, Sybil H.
    Ruiz-Soto, Rodrigo
    Palomba, Lia
    BLOOD, 2014, 124 (21)
  • [37] Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease
    Cai, Tianyu
    Black, Kathryn L.
    Naqvi, Ammar S.
    Taylor, Deanne
    Zhao, Ming
    Yuan, Qi
    Sugita, Mayumi
    Galetto, Roman
    Gouble, Agnes
    Smith, Julianne N. P.
    Cavazos, Antonio
    Han, Lina
    Zhang, Qi
    Kuruvilla, Vinitha Mary
    Ma, Helen
    Konoplev, Sergej
    Tang, Guilin
    Gu, Jun
    Su, Xiaoping
    Neelapu, Sattva S.
    Lane, Andrew A.
    Kantarjian, Hagop M.
    Guzman, Monica L.
    Pemmaraju, Naveen
    Thomas-Tikhonenko, Andrei
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [38] BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines
    van der Lee, Miranda M. C.
    van Achterberg, Tanja
    Hersmus, Kaylee
    Brouwers-Vos, Annet
    van der Vleuten, Monique
    Pruis, Maurien
    Kappers, Wendy
    Verheijden, Gijs
    Huls, Gerwin
    van Wigcheren, Glenn
    Ubink, Ruud
    Sesink, Aloys
    MacInnes, Alyson
    Schuringa, Jan Jacob
    Dokter, Wim
    CANCER RESEARCH, 2024, 84 (06)
  • [39] IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Cortes, Jorge E.
    Traer, Elie
    Wang, Eunice S.
    Erba, Harry P.
    Blum, William
    Arana-Yi, Cecilia
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Towles, Jeanette
    Zweidler-McKay, Patrick A.
    DeAngelo, Daniel J.
    BLOOD, 2017, 130
  • [40] Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
    Shah, Manisha H.
    Lorigan, Paul
    O'Brien, Mary E. R.
    Fossella, Frank V.
    Moore, Kathleen N.
    Bhatia, Shailender
    Kirby, Maurice
    Woll, Penella J.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 290 - 299